[In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer]

Pathologe. 2012 Nov:33 Suppl 2:307-10. doi: 10.1007/s00292-012-1663-z.
[Article in German]

Abstract

The introduction of total genome sequencing led to the confirmation that tumors show substantial genetic heterogeneity. This phenomenon, which describes the presence of different genetic cell clones within a tumor also complicates the diagnostics of HER2. This article gives a review of new knowledge on polysomy 17 and genetic tumor heterogeneity in connection with HER2 determination of breast cancer.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Aneuploidy
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Breast / pathology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology*
  • Chromosomes, Human, Pair 17 / genetics*
  • Female
  • Gene Expression Regulation, Neoplastic / genetics*
  • Genetic Heterogeneity*
  • Humans
  • In Situ Hybridization*
  • Polyribosomes / genetics*
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / genetics*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab